On-demand plerixafor added to high-dose cyclophosphamide and pegylated recombinant human granulocyte colony-stimulating factor in the mobilization of patients with multiple myeloma: a treatment with high effectiveness, convenient, and affordable cost
On-demand Plerixafor zusätzlich zu Hochdosis-Cyclophosphamid und pegyliertem rekombinantem humanem G-CSF bei der Mobilisierung von Patient:innen mit multiplem Myelom: hohe Wirksamkeit, praktisch und kostengünstig
Frontiers in Oncology · 17.01.2024 · 13
DOI: 10.3389/fonc.2023.1306367 ↗Auf einen Blick
Bei 350 Patient:innen mit multiplem Myelom war HD-Cy plus PEG G-CSF mit oder ohne on-demand Plerixafor mit höheren CD34+-Zellzahlen und mehr erfolgreichen Mobilisierungen verbunden.
Fragestellung
Wie wirksam und kosteneffektiv ist HD-Cy plus PEG G-CSF mit on-demand Plerixafor bei der Mobilisierung von Patient:innen mit multiplem Myelom?
Methode
Retrospektive Analyse von 350 Patient:innen mit multiplem Myelom; Vergleich von Cy+PEG G-CSF+/-PXF, Cy+PEG G-CSF, Cy+G-CSF und G-CSF+PXF.
Ergebnisse
Medianer CD34+-Zellwert: 8,79 vs. 4,96 vs. 4,65 vs. 2,99; P<0,001. >6×10^6/kg: 77,3 % vs. 41,8 % vs. 37,3 % vs. 8,3 %; P<0,001. Neutropenisches Fieber: 3,0 % in der Cy+PEG G-CSF+/-PXF-Gruppe.
Schlussfolgerung der Autor:innen
Die Kombination aus on-demand Plerixafor mit HD-Cy und PEG G-CSF bietet laut Autor:innen eine kosteneffektive Strategie mit hoher Mobilisierungserfolgsrate und wenigen Injektionen.
Kernaussagen
- Cy+PEG G-CSF+/-PXF zeigte die höchsten CD34+-Zellzahlen
- 77,3 % erreichten >6×10^6/kg CD34+-Zellen
- Neutropenisches Fieber trat bei 3,0 % auf
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 17.01.2024. Verfasst von Li-Qiong Hou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Mobilisation
Abstract (Originalsprache)
Objective
The combination of high-dose cyclophosphamide (HD-Cy) (3g/m 2 ) plus granulocyte colony-stimulating factor (G-CSF) and on-demand plerixafor (PXF) has been considered an effective mobilization regimen of patients with multiple myeloma(MM). However, the daily multi-injection regimen of G-CSF poses challenges. This study delves into the efficiency and cost implications of a novel approach, using HD-Cy alongside pegylated G-CSF (PEG G-CSF) and on-demand PXF. Unlike G-CSF, which necessitates daily injections, the half-life of PEG G-CSF extended allows for a single injection.
Methods
A retrospective analysis was conducted on 350 MM patients, which were categorized based on their mobilization regimens: Cy+PEG G-CSF+/-PXF (n=66), Cy+PEG G-CSF (n=91), Cy+ G-CSF (n=169), and G-CSF+PXF (n=24).
Results
Mobilization with Cy+PEG G-CSF+/-PXF(8.79)yielded a notably higher median CD34 + cell count compared to the other regimens: Cy+PEG G-CSF(4.96), Cy+G-CSF (4.65), and G-CSF+PXF (2.99) (P<0.001). The percentage of patients who achieved >6×10 6 /kg CD34+ cells was significantly higher in the Cy+PEG G-CSF+/-PXF group (77.3%) than in the other mobilization regimens: Cy+PEG G-CSF (41.8%), Cy+ G-CSF (37.3%), and G-CSF+PXF (8.3%) (P<0.001). From a cost perspective, the Cy+PEG G-CSF+/-PXF approach was more economical than the G-CSF+PXF strategy but was marginally costlier than the other two methods. A multivariate assessment highlighted that the combination of Cy+PEG G-CSF with on-demand PXF had a superior potential to achieve the desired harvest (6×10 6 /kg) compared to the Cy+PEG G-CSF protocol without PXF. The incremental cost-effectiveness ratio for each 1% increase in the probability of achieving a successful optimal harvest was $ 97.02 per patient. The incidence of neutropenic fever was 3.0% in the Cy+PEG G-CSF+/-PXF group.
Conclusion
The combination of on-demand PXF with HD-Cy and PEG G-CSF offers a cost-effective approach with a high mobilization success rate, manageable side effects, and the convenience of fewer injections. It stands as a promising mobilization strategy for MM patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Zitieren
APA
Hou, L. Q., Liu, J. R., Gu, J. L., Chen, M. L., Kuang, L. F., Huang, B. H., Zou, W. Y., & Li, J. (2024). On-demand plerixafor added to high-dose cyclophosphamide and pegylated recombinant human granulocyte colony-stimulating factor in the mobilization of patients with multiple myeloma: a treatment with high effectiveness, convenient, and affordable cost. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1306367
Vancouver
Hou LQ, Liu JR, Gu JL, Chen ML, Kuang LF, Huang BH, et al. On-demand plerixafor added to high-dose cyclophosphamide and pegylated recombinant human granulocyte colony-stimulating factor in the mobilization of patients with multiple myeloma: a treatment with high effectiveness, convenient, and affordable cost. Frontiers in Oncology. 2024;13. doi:10.3389/fonc.2023.1306367
BibTeX
@article{Hou2024,
author = {Hou, Li-Qiong and Liu, Jun-Ru and Gu, Jing-Li and Chen, Mei-Lan and Kuang, Li-Fen and Huang, Bei-Hui and Zou, Wai-Yi and Li, Juan},
title = {On-demand plerixafor added to high-dose cyclophosphamide and pegylated recombinant human granulocyte colony-stimulating factor in the mobilization of patients with multiple myeloma: a treatment with high effectiveness, convenient, and affordable cost},
journal = {Frontiers in Oncology},
year = {2024},
volume = {13},
doi = {10.3389/fonc.2023.1306367}
}
EUVIMED